February 28, 2017 / 12:20 PM / 6 months ago

BRIEF-Pfizer says FDA accepts Biologics License Application for Avelumab for priority review

Feb 28 (Reuters) - Pfizer Inc

* Pfizer Inc - FDA has set a prescription drug user fee act (PDUFA) target action date of august 27, 2017, for Avelumab in this indication

* FDA accepts the Biologics License Application for Avelumab for the treatment of metastatic urothelial carcinoma for priority review Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below